Price · as of 2025
$75.81
Market cap 31.19B
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | $72.10 | -5% |
| P/E | 18.97 | |
| P/B | 15.22 | |
| P/S | 5.35 | |
| EV/EBITDA | 14.22 | |
| PEG | 188.62 | |
| P/TBV | -116.81 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $30.35 | $24.95 | |||
| 2013 | $27.45 | $30.05 | |||
| 2014 | $42.05 | $31.43 | |||
| 2015 | $38.20 | $28.01 | |||
| 2016 | $49.06 | $33.29 | |||
| 2017 | $78.27 | $52.58 | |||
| 2018 | $86.11 | $66.05 | |||
| 2019 | $128.46 | $72.32 | |||
| 2020 | $143.84 | $82.50 | |||
| 2021 | $175.66 | $101.99 | |||
| 2022 | $154.37 | $84.10 | |||
| 2023 | $175.66 | $100.06 | |||
| 2024 | $166.04 | $108.40 | |||
| 2025 | $114.32 | $99.18 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- CEO
- Kristin C. Peck
- Employees
- 14.5K
- Beta
- 0.75
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ZTS | Zoetis Inc. | $75.81 | 31.19B | $99.18 | +31% | 18.97 | 15.22 | 5.35 | 14.22 | 188.62 | -116.81 | 70.49% | 38.00% | 28.23% | 65.99% | 28.56% | 18.00% | 2.85 | 14.80 | 3.03 | 1.75 | 1.76 | 10.05% | 2.28% | -0.65% | 4.50% | 1.30 | 22.78% | 1.75% | 33.30% | 8.13% | 16.09 | 25.35 | 6.11 | 5.48 |
| ARGX | argenx SE | $865.04 | 53.79B | $668.91 | -23% | 40.74 | 5.86 | 10.34 | 29.43 | 76.01 | 6.09 | 89.15% | 25.39% | 31.11% | 16.44% | 41.16% | 14.16% | 0.01 | 258.36 | 5.23 | 4.62 | -2.60 | 53.60% | 89.64% | -658.96% | 1.97% | 0.64 | 32.95% | 0.00% | 0.00% | 4.53% | 36.58 | 45.69 | 9.29 | 20.55 |
| BDX | Becton, Dickinson and Com… | $176.86 | 48.73B | $147.75 | -16% | 25.56 | 1.69 | 1.96 | 12.35 | — | -4.04 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -0.51% | 8.23% | -13.11% | 6.23% | 0.41 | 6.01% | 2.79% | 71.30% | 8.38% | 23.74 | 22.93 | 2.80 | 1.85 |
| CI | Cigna Corporation | $282.49 | 74.65B | $437.32 | +55% | 11.24 | 1.69 | 0.26 | 8.14 | 13.55 | -2.22 | 9.45% | 3.32% | 2.17% | 15.20% | 11.53% | 4.01% | 0.75 | 6.61 | 0.85 | 0.65 | 2.05 | 82.92% | 11.26% | -6.34% | 11.87% | 0.17 | 12.88% | 2.28% | 25.60% | 8.30% | 10.34 | 11.26 | 0.34 | 2.66 |
| COR | Cencora, Inc. | $320.46 | 62.35B | $255.44 | -20% | 41.82 | 43.48 | 0.20 | 19.25 | 732.37 | -4.11 | 3.16% | 1.14% | 0.48% | 145.58% | 42.46% | 2.18% | 7.13 | 8.69 | 0.90 | 0.51 | 1.70 | 5.71% | 9.31% | 6.99% | 4.89% | 0.07 | 53.77% | 0.67% | 27.90% | 1.33% | 19.72 | 22.43 | 0.22 | 4.91 |
| ELAN | Elanco Animal Health Inco… | $22.12 | 11.05B | $21.89 | -1% | -49.08 | 1.74 | 2.42 | 21.98 | — | -6.94 | 43.48% | 5.34% | -4.92% | -3.67% | 2.52% | -1.79% | 0.61 | 1.15 | 2.17 | 0.93 | 5.14 | -169.12% | 6.22% | -27.92% | 2.49% | 0.35 | 2.84% | 0.00% | 0.00% | 3.35% | 58.97 | 52.32 | 3.15 | 1.36 |
| ELV | Elevance Health Inc. | $394.20 | 85.49B | $217.75 | -45% | 11.31 | 1.46 | 0.32 | 9.09 | — | 14.76 | 25.56% | 4.07% | 2.84% | 13.29% | 10.26% | 4.75% | 0.76 | 5.79 | 1.24 | 1.24 | 2.46 | -2.18% | 12.62% | -30.27% | 4.96% | 0.21 | 4.76% | 2.39% | 27.00% | 7.50% | 10.82 | 27.65 | 0.44 | 2.81 |
| HLN | Haleon plc | $10.03 | 44.17B | $22.85 | +128% | 20.16 | 2.00 | 2.98 | 13.94 | 161.29 | -3.58 | 63.35% | 21.87% | 14.78% | 10.01% | 7.95% | 4.88% | 0.52 | 7.25 | 0.92 | 0.70 | 2.53 | 12.50% | -1.81% | -3.91% | 6.00% | 0.46 | 8.27% | 1.82% | 36.70% | 5.70% | 16.64 | 20.37 | 3.64 | 2.49 |
| IDXX | IDEXX Laboratories, Inc. | $586.67 | 46.28B | $341.18 | -42% | 43.38 | 28.63 | 10.68 | 31.90 | 192.06 | 42.50 | 61.80% | 31.60% | 24.62% | 66.20% | 45.37% | 31.89% | 0.67 | 35.54 | 1.17 | 0.76 | 0.61 | 22.59% | 10.42% | 31.99% | 2.29% | 1.03 | 43.92% | 0.00% | 0.00% | 2.65% | 34.45 | 44.48 | 10.89 | 21.16 |
| REGN | Regeneron Pharmaceuticals… | $784.36 | 80.81B | $1,047.09 | +33% | 17.29 | 2.49 | 5.43 | 12.37 | 211.12 | 2.60 | 85.35% | 24.95% | 31.41% | 14.87% | 12.73% | 11.50% | 0.09 | 81.69 | 4.13 | 3.28 | -0.07 | 8.19% | 0.99% | 11.35% | 5.24% | 1.14 | 16.86% | 0.48% | 8.20% | 6.38% | 20.12 | 17.64 | 5.02 | 7.31 |
| TAK | Takeda Pharmaceutical Com… | $17.45 | 55.53B | $28.65 | +64% | -50.96 | 0.99 | 1.62 | 8.49 | -56.56 | -5.31 | 51.06% | 11.99% | 4.26% | -2.06% | 3.65% | -1.02% | 0.63 | 1.51 | 1.27 | 0.61 | 3.03 | 90.10% | 4.28% | -7.50% | 8.08% | 0.43 | 5.41% | 4.02% | -205.00% | 4.69% | 21.04 | 19.24 | 2.52 | 1.18 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($72.10 ÷ $75.81) − 1 = -4.89% (IC, example).